Viking Stock: The cruise leader gave up a key benchmark this past week during the ongoing stock market weakness.

This little-known biotech could have a big hit on its hands with VK2735, a GLP-1 weight loss drug candidate.

What Happened? A number of stocks fell in the afternoon session after geopolitical uncertainty and a sharp rise in oil prices ...

But even before it might obtain approval for its key drug, VK2735, there could be a catalyst that gives the healthcare stock ...

Viking Therapeutics, Inc. stock has surged nearly 1,500% since 2023, driven by the promising GLP-1/GIP receptor agonist VK-2735 for obesity. VK-2735's Phase 2 data showed weight loss comparable to ...

Financial giants have made a conspicuous bullish move on Viking Therapeutics. Our analysis of options history for Viking Therapeutics VKTX revealed 12 unusual trades. Delving into the details, we ...

Explore the exciting world of Viking Holdings (NYSE: VIK) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and ...

GIP obesity drug enters Phase 3 with strong cash runway, but rising competition and trial risk. Click for this VKTX update.

Investors with a lot of money to spend have taken a bullish stance on Viking Therapeutics (NASDAQ:VKTX). And retail traders should know. We noticed this today when the positions showed up on publicly ...

CHARLOTTE, N.C., Jan. 27, 2025 /PRNewswire/ -- Viking Mergers & Acquisitions celebrated a highly successful Q4 in 2024, closing 19 deals on behalf of its clients with a total transaction value of $115 ...